Trial Profile
A Randomized, Double-masked, Parallel Group Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery (Levofloxacin 0.5% Ophthalmic Solution as a Comparator) - Phase III, Confirmatory Study of Perioperative Bacteria Eradication -
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2017
Price :
$35
*
At a glance
- Drugs Levofloxacin (Primary)
- Indications Bacterial infections
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 10 Oct 2017 Status changed from recruiting to completed.
- 15 Oct 2015 New trial record